A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects with Autism Spectrum Disorder [1]
The primary objective of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of ASD during 12 weeks of treatment.
Study Length:
Approximately 4 months
Disorder/Condition:
Autism
Inclusion Criteria:
Males and Females, ages 13-35 with ASD
Study Title (brief):
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects with Autism Spectrum Disorder
Study Description (brief):
The primary objective of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of ASD during 12 weeks of treatment.
Study Contact:
Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org [2]
Study Location:
Nathan Kline Institute, Orangeburg, NY